ISDA

Deposition Date 2012-10-13

Release Date 2012-11-14

Last Version Date 2023-09-20

Entry Detail

PDB ID:

4HJO

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Crystal structure of the inactive EGFR tyrosine kinase domain with erlotinib

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.75 Å

R-Value Free:

0.25

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Epidermal growth factor receptor
Gene (Uniprot):EGFR
Mutations:V924R
Chain IDs:A
Chain Length:337
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00533 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

AQ4

Primary Citation

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.

Park, J.H, Liu, Y, Lemmon, M.A, Radhakrishnan, R.Show

Biochem.J. 448 417 423 (2012)

PMID: 23101586 DOI: 10.1042/BJ20121513

Abstact

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.

Legend

Protein

Chemical

Disease

Primary Citation of related structures